KIRs and their HLA ligands in Remitting-Relapsing Multiple Sclerosis

Journal of Neuroimmunology

Volumn 229, Issue 1-2, 2010, Pages 232-237

  Fusco, Caterina ^a   Guerini, Franca Rosa ^b   Nocera, Giustina ^c   Ventrella, Gianluca ^d   Caputo, Domenico ^b   Valentino, Maria Antonietta ^a   Agliardi, Cristina ^b   Gallotti, Jacopo ^c   Morra, Vincenzo Brescia ^d   Florio, Ciro ^a   Clerici, Mario ^b,e   Lombardi, Maria Luisa ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

HLA KIR ligands; KIRs; Multiple sclerosis

Indexed keywords

GLATIRAMER; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA C2 ANTIGEN; HLA CW ANTIGEN; HLA DR ANTIGEN; INTERFERON; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE FUNCTION; GENE INTERACTION; GENE LOCUS; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NEUROPROTECTION; POPULATION RESEARCH; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; FEMALE; GENOTYPE; HLA ANTIGENS; HUMANS; LIGANDS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ODDS RATIO; RECEPTORS, KIR; YOUNG ADULT;

EID: 78650226799     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.08.004     Document Type: Article

References (40)

1. Airas L., Saraste M., Rinta S., Elovaara I., Huang Y.H., Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin. Exp. Immunol. 2007, 151:235-243.
2. Alter G., Rihn S., Walter K., Nolting A., Martin M., Rosenberg E.S., Miller J.S., Carrington M., Altfeld M. HLA Class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:6798-6805.
3. Arnheim L., Dillner J., Sanjeevi C.B. A population-based color study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. Tissue Antigens 2005, 65:252-259.
4. Barcellos L.F., Oksenberg J.R., Begovich A.B., Martin E.R., Schmidt S., Vittinghoff E., Goodin D.S., Pelletier D., Lincoln R.R., Bucher P., Swerdlin A., Pericak-Vance M.A., Haines J.L., Hauser S.L., Multiple Sclerosis Genetics Groupe HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 2003, 72:710-716.
5. Bashirova A.A., Martin M.P., McVicar D.W., Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu. Rev. Genomics Hum. Genet. 2006, 7:277-300.
6. Bergamaschi L., Leone M.A., Fasano M.E., Guerini F.R., Ferrante D., Bolognesi E., Barizzone N., Corrado L., Naldi P., Agliardi C., Dametto E., Salvetti M., Visconti A., Galimberti D., Scarpini E., Vercellino M., Bergamaschi R., Monaco F., Caputo D., Momigliano-Richiardi P., D'Alfonso S. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes Immun. 2010, 11(2):173-180.
7. Bontadini A., Testi M., Cuccia M.C., Martinetti M., Carcassi C., Chiesa A., Cosentini E., Dametto E., Frison S., Iannone A.M., Lombardo C., Malagoli A., Mariani M., Mariotti L., Mascaretti L., Mele L., Miotti V., Nesci S., Ozzella G., Piancatelli D., Romeo G., Tagliaferri C., Vatta S., Andreani M., Conte R. Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population. J. Transl. Med. 2006, 4:44-52.
8. Boyton R.J., Altmann D.M. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin. Exp. Immunol. 2007, 149:1-8.
9. Brynedal B., Duvefelt K., Jonasdottir G., Roos I.M., Akesson E., Palmgren J., Hillert J. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2007, 2:e664.
10. Butsch Kovacic M., Martin M., Gao X., Fuksenko T., Chen C.J., Cheng Y.J., Chen J.Y., Apple R., Hildesheim A., Carrington M. Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2673-2677.
11. Carrington M., Wang S., Martin M.P., Gao X., Schiffman M., Cheng J., Herrero R., Rodriguez A.C., Kurman R., Mortel R., Schwartz P., Glass A., Hildesheim A. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 2005, 201:1069-1075.
12. Correale J., Villa A. Role of CD8+ CD25+ Foxp3+ Regulatory T Cells in Multiple Sclerosis. Ann. Neurol. 2010, 67:625-638.
13. Dean G., McLoughlin H., Brady R., Adelstein A.M., Tallett-Williams J. Multiple sclerosis among immigrants in Greater London. B.M.J. 1976, 1:861-864.
14. Friese M.A., Fugger L. Pathogenic CD8+ T Cells in Multiple Sclerosis. Ann. Neurol. 2009, 66:132-141.
15. Fusco C., Andreone V., Coppola G., Luongo V., Guerini F.R., Pace E., Florio C., Pirozzi G., Lanzillo R., Ferrante P., Vivo P., Mini M., Macrì M., Orefice G., Lombardi M.L. HLA-DRB1*1501 and response to copolymer-1 therapy in remitting relapsing multiple sclerosis. Neurology 2001, 57:1976-1979.
16. Gödde R., Rohde K., Becker C., Tollat M.R., Entz P., Suk A., Müller N., Sindern E., Haupts M., Schimrigk S., Nürnberg P., Epplen J.T. Association of the HLA region with multiple sclerosis as confirmed by a genome screen using >10, 000 SNPs on DNA chips. J. Mol. Med. 2005, 83:486-494.
17. Hsu K.C., Liu X.R., Selvakumar A., Mickelson E., O'Reilly R.J., Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J. Immunol. 2002, 169:5118-5129.
18. Khakoo S.I., Carrington M. KIR and disease: a model system or system of models?. Immunol. Rev. 2006, 214:186-201. Review.
19. Kulkarni S., Martin M.P., Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin. Immunol. 2008, 20:343-352.
20. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
21. Lorentzen A.R., Karlsen T.H., Olsson M., Smestad C., Mero I.L., Woldseth B., Sun J.Y., Senitzer D., Celius E.G., Thorsby E., Spurkland A., Lie B.A., Harbo H.F. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann. Neurol. 2009, 65:658-666.
22. Martin M., Gao X., Lee J.H. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 2002, 31:429-434.
23. Martinez-Rodriguez J.E., Saez-Borderias A., Munteis E., Romo N., Roquer J., Lopez-Botet M. Natural killer receptors distribution in multiple sclerosis: relation to clinical course and interferon-beta therapy. Clin. Immunol. 2010, 10.1016/ j.clim.2010.06.002.
24. Matsumoto Y., Kohyama K., Aikaw Y., Shin T., Kawazoe Y., Suzuki Y., Tanuma N. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur. J. Immunol. 1998, 28:1681-1688.
25. Middleton D., Gonzelez F. The extensive polymorphism of KIR genes. Immunology 2010, 129:8-19.
26. Middleton D., Williams F., Halfpenny I.A. KIR genes. Transpl. Immunol. 2005, 14:135-142.
27. Negishi K., Waldeck N., Chandy G., Buckingham B., Kershnar A., Fisher L., Gupta S., Charles M.A. Natural killer and islet killer cell activities in type 1 (insulin dependent) diabetes. Diabetologia 1986, 29:352-357.
28. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
29. Riley J.K., Yokoyama W.M. NK cell tolerance and the maternal-fetal interface. Am. J. Reprod. Immunol. 2008, 59:371-387.
30. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sørensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sá M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
31. Sadovnick A.D., Ebers G.C., Dyment D.A., Risch N.J., C.C.S.Group Evidence for genetic basis of multiple sclerosis. Lancet 1996, 347:1728-1730.
32. Segal B.M. The role of natural killer cells in curbing neuroinflammation. J. Neuroimmunol. 2007, 191(1-2):2-7.
33. Shi F.D., Van K.L. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat. Rev. Immunol. 2006, 6:751-760. Review.
34. Takahashi K., Miyake S., Kondo T., Terao K., Hatakenaka M., Hashimoto S., Yamamura T. Natural killer type 2 bias in remission of multiple sclerosis. J. Clin. Invest. 2001, 107(5):R23-R29.
35. Takahashi K., Aratami T., Endoh M., Miyake S., Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004, 127:1917-1927.
36. Weinshenker B.G., Kantarci O.H. Seeking genes for MS: big risks for big gains. Neurology 2000, 54:542-544.
37. Xu W., Fazekas G., Hara H., Tabira T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 163:24-30.
38. Yen J.H., Moore B.E., Nakajima T., Scholl D., Schaid D.J., Weyand C.M., Goronzy J.J. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J. Exp. Med. 2001, 193:1159-1167.
39. Yeo T.W., The International Multiple Sclerosis Genetics Consortium A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann. Neurol. 2007, 61:228-236.
40. Zhang B., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186:1677-1687.